Everyone is selling Indian IT. The Nifty IT index has underperformed by 15% since February. Infosys is down 25% from its 52-week high. GenAI will "kill IT services," the bears say. Here is why they might be spectacularly wrong — and why Infosys at ₹1,300 deserves a closer look.
CMP
₹1,300
−25% from 52W high of ₹1,728
Q3 FY26 Revenue
₹45,479 Cr
+8.9% YoY
Large Deals
$4.8 Bn TCV
57% net new
Market Cap
₹5.28L Cr
PE ~19x — cheapest in 3 years
The AI narrative in Indian IT has flipped from tailwind to headwind in just six months. In late 2025, every deal win with an "AI component" sent stocks soaring. By March 2026, the same narrative became a weapon: AI will automate coding, destroy billing hours, and compress margins. The truth, as always, lies somewhere in between — and the market has priced in far too much fear at current levels.
The AI Paradox: Threat or Biggest Opportunity Since Cloud?
This is the central question every Infosys investor must answer. Let us start with what the bears get right — then dismantle the rest.
The bear case
GenAI can write code, test software, and automate repetitive tasks. If a project that took 100 engineers now takes 60, that is a 40% revenue hit for IT services firms. AI-led "deflation" compresses deal values. Accenture and the hyperscalers (AWS, Azure, GCP) eat the consulting layer that Infosys occupies.
What the bears miss
AI does not reduce IT spending — it redirects it. Every enterprise AI deployment needs data engineering, integration, change management, security, and ongoing optimization. Gartner projects that by 2026, over 80% of enterprises will have deployed GenAI apps — up from 5% in 2023. Someone has to build, integrate, and maintain all of that. That someone is Infosys.
Infosys has trained over 250,000 employees in AI and GenAI. It has deployed 300+ Agentic AI solutions across clients. It co-launched GenAI solutions with NVIDIA. This is not a company being disrupted — it is a company doing the disrupting. The $300-400 billion AI services opportunity by 2030 is Infosys's to lose.
Infosys Topaz — The AI-First Platform
AI-Trained Employees
250,000+
Largest AI-skilled IT workforce
Agentic AI Solutions
300+
Deployed across clients
AI Revenue Opportunity
$300-400 Bn
Industry TAM by 2030
Cloud Revenue
30% of Total
Growing 25% YoY
Infosys Topaz is the company's AI-first suite that embeds GenAI into every engagement — not as an add-on, but as a core delivery lever. The NVIDIA-powered BankingSLM and ITOpsSLM are industry-specific small language models that give Infosys a differentiated edge in verticals where generic AI cannot compete.
Q3 FY26: The Quarter That Changed The Narrative
| Metric | Q3 FY26 | Q3 FY25 | Change |
|---|---|---|---|
| Revenue | ₹45,479 Cr | ₹41,764 Cr | +8.9% |
| EBIT | ₹9,479 Cr | ₹9,269 Cr | +2.3% |
| Net Profit | ₹6,654 Cr | ₹6,806 Cr | −2.2% |
| EBIT Margin | 20.8% | 22.2% | −140 bps |
| Large Deal TCV | $4.8 Bn | $3.2 Bn | +50% |
| New Clients Added | 121 | — | 1,949 total |
The headline — "profit dips" — sent the stock down initially. But look deeper: revenue grew 8.9%, deal wins hit $4.8 billion (57% net new), and Infosys raised its FY26 guidance to 3–3.5% CC growth from 2–3%. The profit dip was entirely due to a one-time ₹1,289 crore labour code provision. Adjusted margin actually improved 20bps sequentially to 21.2%. The market punished a great quarter because it could not read past the headline.
Q4 FY26 Preview: What To Expect on April 23
The Q4 results are less than three weeks away. Here is what analysts are expecting:
| Metric | Q4 FY26E | Q3 FY26 | Expected Change |
|---|---|---|---|
| Revenue | ₹46,700 Cr | ₹45,479 Cr | +2.7% QoQ |
| Net Profit | ₹7,450–7,750 Cr | ₹6,654 Cr | +12–16% QoQ |
| EBIT Margin | 20.6–20.8% | 20.8% | Stable to −20bps |
| CC Revenue Growth | −0.2% QoQ | +0.6% QoQ | Soft (seasonal) |
What to watch
- FY27 guidance — this is the main event. JM Financial expects 2–4% CC growth; ICICI Securities expects 3–5%. Anything above 4% would be a major positive surprise.
- Deal pipeline commentary — if the $11.7 billion FY26 TCV target is met, it signals sustained demand despite macro headwinds.
- AI deal mix — what percentage of new deals have an AI component? This number is the real tell on whether GenAI is cannibalising or creating revenue.
- Final dividend — the board will consider a final FY26 dividend at the same meeting.
Q4 will be soft seasonally — fewer billing days, visa costs, wage inflation. The real catalyst is FY27 guidance. If Infosys guides 4%+ CC growth, expect a sharp re-rating from current depressed levels.
Project Maximus: The Margin Machine
Project Maximus is Infosys's internal cost optimisation engine — think of it as the company applying its own AI and automation tools to itself. It has been quietly compressing costs while the headline margin looks flat.
Margin Walk — What Is Really Happening
The FY26 margin guidance of 20–22% looks conservative. Project Maximus savings, rupee depreciation benefit, and improving utilisation give Infosys levers to expand margins even in a soft revenue environment. The one-time labour code provision in Q3 masked the underlying improvement.
Revenue Mix: Where The Growth Is (And Is Not)
Sector-wise growth (Q3 FY26 YoY)
Geographic growth (Q3 FY26 YoY)
The geographic mix is the most interesting signal. Europe growing 13.3% while North America declines 1.2% shows Infosys is successfully diversifying away from US-centric revenue risk. The $465 million Optimum Healthcare IT acquisition and $95 million Stratus Global deal further expand its footprint.
Peer Comparison: How Does Infosys Stack Up?
| Metric | Infosys | TCS | HCL Tech | Wipro |
|---|---|---|---|---|
| Market Cap | ₹5.28L Cr | ₹8.90L Cr | ₹3.68L Cr | ₹2.04L Cr |
| PE (TTM) | ~19x | ~22x | ~24x | ~15x |
| Q3 Revenue Growth | 8.9% | 5.6% | 8.6% | 0.5% |
| EBIT Margin | 20.8% | 24.5% | 19.3% | 16.2% |
| ROE | 32.7% | 48.3% | 24.1% | 14.8% |
| Large Deal TCV | $4.8 Bn | $12.2 Bn | $2.1 Bn | $1.5 Bn |
| Debt/Equity | 0.11 | 0.02 | 0.05 | 0.20 |
Infosys trades at a PE of ~19x — the cheapest among Tier-1 IT names except Wipro, which has execution issues. For a company growing revenue at 8.9% with 32.7% ROE and $4.8 billion in deal wins, this valuation is not "expensive" — it is a discount. Kotak prefers TCS and Infosys as their top picks in Indian IT.
Valuation: Is the Market Being Too Harsh?
The Nifty IT index trades at 17.8x one-year forward earnings — 16% below its 10-year average. Infosys at ~19x PE is near its decade-low valuations, having ranged from 15x to 35x over the past 10 years.
| Valuation Metric | Current | 5-Year Avg | 10-Year Avg |
|---|---|---|---|
| PE (TTM) | 19x | 27x | 23x |
| EV/EBITDA | 11.8x | 18x | 16x |
| P/B | 7.2x | 9x | 8x |
| Dividend Yield | 3.2% | 2.1% | 2.3% |
The dividend yield at 3.2% is the highest it has been in years. When high-quality IT companies start yielding more than fixed deposits, contrarian investors often pay attention.
Analyst Price Targets
| Source | Target | View |
|---|---|---|
| Nomura | ₹1,810 | Buy |
| YES Securities | ₹1,672 | Buy |
| HDFC Securities | ₹1,600 | Buy |
| JM Financial | ₹1,525 | — |
| Consensus (44 analysts) | ₹1,782 avg | 33 Buy, 10 Hold, 2 Sell |
The consensus target of ₹1,782 implies ~37% upside from the current ₹1,300 level. Even the most bearish analyst target of ₹1,290 is essentially the current price — meaning the downside is already priced in.
Technical Setup: Key Levels
| Level | Price | Signal |
|---|---|---|
| 52-Week Low | ₹1,215 | Strong floor — tested and held |
| Support 1 | ₹1,260 | Recent intraday low |
| Current Price | ₹1,300 | Near support zone |
| Resistance 1 | ₹1,430 | 50-DMA cluster |
| Resistance 2 | ₹1,550 | 200-DMA / major resistance |
| 52-Week High | ₹1,728 | January 2025 peak |
Indicators
Technically, the stock is in a downtrend. But the risk-reward at ₹1,260–1,300 is asymmetric: downside to ₹1,215 is just 7%, while upside to consensus target is 37%. For traders, a break above ₹1,430 with volume confirms trend reversal.
5 Catalysts That Could Re-Rate The Stock
- Q4 FY26 Results (April 23) — Strong FY27 guidance above 4% CC growth would shatter the "AI kills IT" narrative and trigger institutional buying.
- AI Deal Acceleration — If Infosys reports that 30%+ of new deal TCV has an AI component, it proves AI is a net revenue creator, not a destroyer.
- Fed Rate Cuts & US Recovery — Lower rates in the US would unlock enterprise tech budgets that have been frozen. North America is 60% of Infosys revenue — even a small recovery moves the needle.
- Acquisitions Paying Off — The $560 million in recent acquisitions (Optimum Healthcare IT + Stratus Global) are expected to add ~225bps to FY27 growth. If integration goes smoothly, this becomes a margin-accretive growth lever.
- Rupee Depreciation — With INR at ₹90/USD, every additional rupee of depreciation adds ~40bps to margins. This is a structural tailwind that the market is not pricing in.
5 Risks You Cannot Ignore
- GenAI Deflation Accelerates — If AI-driven productivity gains compress deal values faster than new AI services revenue scales up, margins could shrink. This is the existential risk the bears point to.
- US Macro Slowdown — West Asia conflict escalation, oil price spikes, and potential US recession would freeze enterprise tech spending. IT is a discretionary spend for most clients.
- Wage Inflation — IT talent costs are rising, especially for AI-skilled engineers. If Infosys cannot pass costs through to clients, margins compress from both sides.
- Client Concentration — Top clients contribute disproportionately to revenue. Losing a mega-deal or seeing a top-5 client cut spending would hit growth hard.
- Leadership Transition Risk — CEO Salil Parekh's term was extended through 2027, providing near-term stability. But the market will start pricing in succession risk as 2027 approaches.
Key Considerations by Investment Horizon
Long-term perspective (3–5 years)
Infosys at ~19x PE with 32.7% ROE and 3.2% dividend yield presents an interesting valuation case for one of India's highest-quality companies. Analysts note support levels around ₹1,200–1,350. The IT sector's FY26–28 EPS CAGR of 10.8% suggests growth at a historically low valuation. The key debate is whether AI disrupts or empowers the IT services model.
Medium-term perspective (1–2 years)
The Q4 results on April 23 are the key event to watch. If FY27 guidance surprises positively, analysts project the stock could move toward ₹1,500–1,600. Key risk: if guidance disappoints below 2% CC growth, the stock could test ₹1,215.
Short-term technical observations
The ₹1,260–1,300 zone has acted as a support area. Key support below sits at ₹1,210 (below 52-week low). Resistance at ₹1,430 (50-DMA). The April 23 results are a binary event that could drive significant price movement in either direction.
[CHART:line:Infosys Stock Price (Last 2 Years)]
[CHART:candle:Infosys Daily Chart with Support/Resistance]
[CHART:volume:Infosys Trading Volume Analysis]
Risk-Reward Calculator
Evaluate whether a trade setup is worth taking
Risk-Reward Ratio
1 : 2.0
Risk per Share
$20
Potential Loss
$2,000
Potential Profit
$4,000
This setup meets the minimum 1:2 risk-reward threshold
Price Levels
The Verdict
Infosys at ₹1,300 is being priced as if GenAI will destroy IT services. The counter-argument is that GenAI is creating a $300-400 billion services opportunity, and Infosys is one of three companies globally positioned to capture it (alongside TCS and Accenture). With $4.8 billion in quarterly deal wins, 250,000+ AI-trained employees, a fortress balance sheet, and a 3.2% dividend yield, the bull case rests on strong fundamentals.
At current levels, Infosys presents both significant opportunities and real risks. The AI narrative cuts both ways — it could be the biggest growth engine since the internet, or it could compress billing rates. With 33 of 44 analysts at Buy and 37% potential upside to consensus target, the majority view is positive — but investors should form their own view based on their assessment of how AI reshapes IT services. The Q4 results on April 23 will be a critical data point.
Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Stonqly is not registered with SEBI as a Research Analyst or Investment Adviser. Nothing in this article should be construed as a buy, sell, or hold recommendation for any security. Stock market investments are subject to market risks. Past performance does not guarantee future results. Always conduct your own research and consult a SEBI-registered investment advisor before making any investment decisions.
Comments (0)